ReviewJournal of nephrology2019
Anticoagulation in CKD and ESRD.
Review in Journal of nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- An Overview of Anticoagulant Drugs Pharmacology, Therapeutic Approaches, Limitations and Perspectives.Pharmaceutics · 2026Review
- Heparin: Over 100 Years of Anticoagulation.Handbook of experimental pharmacology · 2026Review
- Cardiovascular Events and Mortality in Patients on Hemodialysis: The Prognostic Value of the CHAMedicina (Kaunas, Lithuania) · 2024Article
- Prescriber perceptions of the safety and efficacy of unfractionated heparin versus low molecular weight heparin in the acute treatment phase: a qualitative study.Journal of pharmaceutical policy and practice · 2024Article
- Choosing the right chronic medication for hemodialysis patients. A short ABC for the dialysis nephrologist.Journal of nephrology · 2023Review
- Patients with end-stage renal disease requiring hemodialysis benefit from percutaneous coronary intervention after non-ST-segment elevation myocardial infarction.Internal and emergency medicine · 2022Article
- Different glomerular filtration rate estimating formula for prescribing DOACs in oldest patients: appropriate dosage and bleeding risk. Post hoc analysis of a prospective cohort.Aging clinical and experimental research · 2022Article
- Therapeutic anticoagulation complications in the elderly: a case report.BMC geriatrics · 2022Article
- Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis.Journal of nephrology · 2021Article
- Article
- Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.Blood transfusion = Trasfusione del sangue · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review we discuss the evolving literature of anticoagulation in the context of the nephrology patient. Whereas CKD patients with atrial fibrillation, should be anticoagulated, the benefit of anticoagulation for those on dialysis remains controversial due to an increased risk of bleeding. The availability of direct oral anticoagulants offers new options for those with CKD. Until studies are available in stage 4 and 5/dialysis, this class of medication should be used with caution in this population. For anticoagulated patients requiring interventional procedures, a risk-based approach should be employed to determine those who will benefit from bridging anticoagulation. Either unfractionated heparin or low molecular weight heparin are adequate choices for bridging anticoagulation. Unfractionated heparin and renally dosed low molecular weight heparin can be safely used in non-end stage CKD patients with an acute coronary syndrome. Similarly, the use of unfractionated heparin and low molecular weight heparin are comparable for thromboembolic prophylaxis in CKD/dialysis and extracorporeal circuit anticoagulation of the dialysis circuit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.